Madison company achieves 94 percent tumor reduction in clinical trial
Cellectar Biosciences has achieved 94 percent tumor reduction in a patient taking part in a clinical trial for the company’s cancer treatment.
The Madison-based pharmaceutical firm’s product is called CLR 131. It’s used to precisely deliver radiation to malignant tumor cells while avoiding healthy cells that would be damaged by the treatment.
The drug is currently being used in a Pha...
Please log in to access subscriber content.
If you don't have a subscription, please contact schmies@wispolitics.com for subscription options on the WisPolitics-State Affairs platform, which is the new home for WisPolitics subscriber products.
